• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society
  • FABA holds Conference on Antimicrobial Resistance Stewardship Series
  • COVID no longer a global health emergency, WHO says
  • Chemist in India loses seven papers of biology, blames outsourcing of images
  • Indian Research scholars express frustration over DST’s tweet, plan stir
  • BioAsia 2023 to be held in February 24-26 in Telangana, India
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    May 22, 2023

    Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society

    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»Prof. P. Reddanna, validated the 12R-LOX as the target for the development of anti-psoriasis drugs

Prof. P. Reddanna, validated the 12R-LOX as the target for the development of anti-psoriasis drugs

0
By Biotech Express on November 19, 2021 Articles, Articles- Editorials, BioResearch - Academic, Biotech News

A team of researchers from the School of Life Sciences, University of Hyderabad comprising Prof. P. Reddanna, Advisory Board Member of Biotech Express, Dr. Kumar Reddy and Dr. Nooruddin Khan and from Dr. Reddy’s Institute of Life Sciences comprising Mr. Harshavardhan Bhuktar, Mr. Sharda Shukla and Prof. Manojit Pal have validated the 12R-LOX as the target for the development of anti-psoriasis drugs through a series of in vitro and in vivo experiments, including generation of 12R-LOX overexpressing transgenic mice and efficacy of 12R-LOX inhibitors.

A recognized feature of psoriasis and other proliferative dermatoses is the accumulation in the skin of the unusual arachidonic acid metabolite, 12R-hydroxyeicosatetraenoic acid (12R-HETE), a product of 12R-Lipoxygenase (12R-LOX). Microarray studies, in humans, reveal that 12R-LOX was pathologically over-expressed during the Psoriasis and other proliferative skin dermatoses. Deletion of 12R-LOX in mice results in impaired development of skin, which accounts for post-natal lethality. Conversely, overexpression of 12R-LOX has been implicated in Psoriasis, while deleterious mutations resulting in inactivation of 12R-LOX results in ichthyosis (skin disorder) characterized by disruption of cell-barrier functions. Thus, 12R-LOX forms a potential target for the development of proliferative skin disorders, including psoriasis.

A team of researchers from the School of Life Sciences, University of Hyderabad (Prof. P. Reddanna, Dr. Kumar Reddy and Dr. Nooruddin Khan) and from Dr. Reddy’s Institute of Life Sciences (Mr. Harshavardhan Bhuktar, Mr. Sharda Shukla and Prof. Manojit Pal) have validated the 12R-LOX as the target for the development of anti-psoriasis drugs through a series of in vitro and in vivo experiments, including generation of 12R-LOX overexpressing transgenic mice and efficacy of 12R-LOX inhibitors. The lead compounds showing efficacy in vitro on the target enzyme and in vivo on animal models have been granted Indian Patent No. 377565 || Title: HETEROCYCLIC COMPOUNDS AS LIPOXYGENASE INHIBITORS, date of grant: 22/9/2021). A PCT has also been filed for this invention (International Publication number WO 2020/255156 A1, 24 Dec 2020).

This invention is the outcome of a collaborative project between the two institutions funded jointly by the Department of Science and Technology (DST) and Dr Reddy’s Laboratories Ltd (DRL), for a project on “12-R-Lipoxygenase as Target for Discovery and Development of Drugs Against Psoriasis”.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society

Indian Research scholars express frustration over DST’s tweet, plan stir

Praj Industries and ESIIC partner to further bioeconomy in Egypt

Leave A Reply Cancel Reply

Current Issue – April 2023
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society May 22, 2023
  • FABA holds Conference on Antimicrobial Resistance Stewardship Series May 22, 2023
  • COVID no longer a global health emergency, WHO says May 18, 2023
  • Chemist in India loses seven papers of biology, blames outsourcing of images May 17, 2023
  • Indian Research scholars express frustration over DST’s tweet, plan stir May 16, 2023
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
  • India’s Clinical Trial Registry might disappear soon and so the history of pharma record August 19, 2022
  • Nearly Half of Pregnant Women in Pfizer Trial Miscarried August 10, 2022
  • Researchers develop Cellulose shoes made by bacteria August 9, 2022
  • Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility August 5, 2022
  • CBI Arrests of CDSCO officials, a Biocon official & Intermediaries in an alleged bribery case exposed Corruption in Govt and Pharma sector July 27, 2022
  • We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO July 26, 2022
  • EVENT HIGHLIGHTS: Genome editing as a novel technology for sustainable development July 24, 2022
  • US Military Doctor Testifies under Oath That She Was ORDERED To ‘Cover up’ COVID Vaccine Injuries July 24, 2022
  • Climatic Effect on Marine Biodiversity and their impact on coral reefs July 23, 2022
  • Highlights of India’s first Biotech startup Expo June 13, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.